Ensayos clínicos

Inclusion Criteria (apply to Aim 3, subject population #4 only):

• Moderate to severely active ulcerative colitis (defined by Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score of ≥2)
• Able to provide informed consent;
• Scheduled for disease severity assessment by endoscopy (colonoscopy or flexible sigmoidoscopy)
• Intended to return to our center for follow-up colonoscopic assessment of response to therapy
• Adjunctive medication may be administered; these include, corticosteroids, thiopurine immunomodulators, methotrexate, 5-aminosalicylate therapies
• Baseline endoscopy is negative for colorectal cancer or dysplasia

Exclusion Criteria:

• Patient has known primary aerodigestive cancer outside of the colon within the last 5 years
• Prior colonic resection
• Prior colonic neoplasia
• Diagnosis of FAP
• Diagnosis of Lynch
• Participation in another clinical trial of novel IBD therapeutic agent
• Use of off-label therapy